Aurigene Discovery Technologies Limited

Novartis Ag

Aurigene Oncology Limited

Um Pharmauji Sdn. Bhd.

Disc Medicine, Inc.

Venkateshwar Rao Gummadi

Susanta Samajdar

Mark G Bock

Christoph Gaul

Saumitra Sengupta

Ajay Gupta

Srikanth Venkatraman

Subramanya Hosahalli

Henrik Moebitz

Srinivas Nanduri

Girish Chandrappa Daginakatte

Rajeev Goswami

Kavitha Nellore

Girish Aggunda Renukappa

Wesley R Balasubramanian

Subhendu Mukherjee

A Bharathi Raja

Murtuza Hadianawala

Wesley Roy Balasubramanian

Mark Gary Bock

The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.

Matriptase 2 inhibitors and uses thereof

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X, X, X, R, R, 'm', ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X, X, X, R, R, 'm', 'n' and &#x2018;p&#x2019; have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.

Compounds and compositions for treating hematological disorders

The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z, Z, R, R, R, 'm' and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.

Indazole compounds as IRAK4 inhibitors

The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X, X, R, R, 'm', 'n' and &#x2018;p&#x2019; have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present application relates to novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors.  The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, Rand Rare as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors.

17a-hydroxylase/C17,20-lyase inhibitors

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, Rand Rare as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors. 

[object Object]

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R, R, R, R, R, R, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided. 

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R, R, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17&#x3b1;-hydroxylase/C-lyase inhibitors.

Growing community of inventors

Bengaluru, India

Venkateshwar Rao Gummadi